Your browser version may not work well with NCBI's Web applications. More information here...
1: J Cell Biol. 2004 Nov 8;167(3):399-403.Click here to read Click here to read Links
Erratum in:
J Cell Biol. 2004 Dec 20;167(6):1255.

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis.

Manning BD.

Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, MA 02115, USA. bmanning@hsph.harvard.edu

Proper regulation of the phosphoinositide 3-kinase-Akt pathway is critical for the prevention of both insulin resistance and tumorigenesis. Many recent studies have characterized a negative feedback loop in which components of one downstream branch of this pathway, composed of the mammalian target of rapamycin and ribosomal S6 kinase, block further activation of the pathway through inhibition of insulin receptor substrate function. These findings form a novel basis for improved understanding of the pathophysiology of metabolic diseases (e.g., diabetes and obesity), tumor syndromes (e.g., tuberous sclerosis complex and Peutz-Jegher's syndrome), and human cancers.

PMID: 15533996 [PubMed - indexed for MEDLINE]

PMCID: PMC2172491